BRISTOL MYERS SQUIBB

I-Mab announced financial results for Q2 2024, highlighting pipeline progress including IND clearance for uliledlimab, a collaboration with Bristol Myers Squibb for givastomig, and promising early data for ragistomig. The company completed divestiture of China operations, reporting $207.5M in cash, with a runway into 2027. Key milestones include Phase 2 studies for uliledlimab in mNSCLC and Phase 1b studies for givastomig in gastric cancer.

Novo Nordisk launches Wegovy® in Australia for weight loss. Xbrane regains certolizumab biosimilar rights. BMS’ Opdivo® gains new NSCLC indication in Australia. Teva’s Q2 revenue grows 7%. Celltrion’s ustekinumab biosimilar approved in Canada. Zydus’ trastuzumab biosimilar approved in Mexico. PBAC agenda includes denosumab & ustekinumab biosimilars. UPC hears omalizumab patent dispute. Biogen’s Leqembi® shows Alzheimer’s benefits. Samsung Bioepis revokes Janssen’s Stelara® patent in UK. Bio-Thera/Sandoz’s bevacizumab biosimilar approved in EU. Roche’s Vabysmo® approved for RVO in EU. FDA approves J&J’s Darzalex Faspro® for multiple myeloma. Formycon’s pembrolizumab biosimilar enters Phase III. US indicts for counterfeit cancer drugs. Roche’s Vabysmo® approved for RVO in Canada. NICE against trastuzumab deruxtecan for HER2-low breast cancer. Amgen’s Xgeva® PFS approved in Korea. FDA alerts on compounded semaglutide imitations. Regeneron disclaims aflibercept patent after adverse IPR decision.

Bristol Myers Squibb reported Q2 earnings and revenue above expectations, raising its full-year guidance. The company plans to cut $1.5 billion in costs by 2025, reinvesting in key brands and R&D. Shares rose nearly 8%. Revenue increased 9% to $12.2 billion, driven by Eliquis and Opdivo sales.

In 2024, global drugmakers like AstraZeneca and Novartis are pursuing deals in China to enhance their drug pipelines and market presence, despite Sino-US tensions. This interest benefits local companies and investors, though risks remain due to political and economic uncertainties. Foreign acquisitions in China's healthcare sector have decreased, with domestic buyers dominating.

Global pharmaceutical companies are increasingly targeting China's expanding healthcare market, driven by its aging population and rising chronic disease rates. Despite geopolitical tensions and regulatory challenges, major deals like AstraZeneca's $1.2 billion acquisition of Gracell Biotechnologies highlight the market's appeal. Investments in local R&D and strategic partnerships are key strategies for navigating China's complex landscape, aiming to introduce innovative treatments and strengthen market presence.

Global drugmakers like Bristol Myers Squibb and Sanofi are pursuing M&A deals in China to enhance drug pipelines and market presence, despite Sino-U.S. tensions and regulatory challenges. Recent deals include AstraZeneca's $1.2B purchase of Gracell Biotechnologies. Political and economic risks, including U.S.-China relations and data transfer restrictions, are significant considerations.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

In Q2 2024, FDA and EMA approved 26 new/expanded indications and 9 new oncology agents, targeting 19 solid tumors and 5 hematologic malignancies. Highlights include 6 NSCLC treatments, 4 tumor-agnostic approvals, and 3 biologics for follicular lymphoma. Key approvals: alectinib, durvalumab, epcoritamab. Safety updates included hepatotoxicity risks and CAR T-cell therapy warnings.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.